7085-55-4|Troxerutin，≥98%|Medlife为MCE，Selleck，麦克林，阿拉丁试剂，罗恩试剂，Sigma，安耐吉试剂，泰坦等同类产品品牌，上海现货，性价比高

您当前的位置：

Troxerutin

类黄酮，Troxerutin 也被称为维生素 P4，是天然生物类黄酮芦丁的三羟乙基化衍生物，其可抑制活性氧 (ROS) 的产生并抑制 ER 应激介导的 NOD 活化。

目录号: PC15116 纯度: ≥98%

CAS No. :7085-55-4

商品编号	规格	价格	会员价	是否有货	数量
PC15116-50mg	50mg	¥392.00	请登录
PC15116-5g	5g	¥931.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

Troxerutin

中文别名

曲克芦丁;3',4',7-三[O-(2-羟乙基)]芦丁;维生素P4;三羟乙基芦丁;羟乙芦丁;托克芦丁;维脑路通;芦丁;曲可芦丁;曲克芦丁标准品;曲克芦丁（槐米提取物）;曲克芦丁（维脑路通）;三-O-(2-羟乙基)芸香苷;三羟乙基芦丁 EP标准品;3,4,7-三[O-(2-羟乙基)]芦丁;羟乙基芦丁;曲克芦丁TROXERUTIN

英文名称

Troxerutin

英文别名

trihydroxyethylrutin;Troxerutin;Trihydroxylrutin;3',4',7-Tris[O-(2-hydroxyethyl)]rutin;3',4',7-TRIS-O-(2-HYDROXYETHYL)RUTIN;TROXERUTIN(P);7,3',4'-trihydroxyethyl rutin;Factor-P-zyma;POSORUTIN;Rufen P-4;RUVEN;Troxerutine;VASTRIBIL;Venoruton;Venoruton P-4;Z-6000;Vitamin P4;Trioxyethylrutin;Factor P-zyma;Tris(hydroxyethyl)rutin;Tris(hydroxyethyl)rutoside;3',4',7-Tris(hydroxyethyl)rutin;Troxerutin (INN);Pherarutin;Venoruton P4;Rufen-P4;Troksevazin;Troxarutin;Veinamitol;Venaroid;Veniten;Helveton;Flebil;7Y4N11PXO8;Pur-Rutin;Veinamitol Pulver;Z 6000;Veno SL;Troxarutin-ratiopharm;Troxerutine [INN-French];Troxerutinum [INN-Latin];Troxerutina [INN-Spanish]

Cas No.

7085-55-4

分子式

C₃₃H₄₂O₁₉

分子量

742.68

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Troxerutin, also known as vitamin P4, is a tri-hydroxyethylated derivative of natural bioflavonoid rutins which can inhibit the production of reactive oxygen species (ROS) and depress ER stress-mediated NOD activation.

性状

Solid

IC50 & Target[1][2]

ROS, NOD

体外研究(In Vitro)

The results reveal that the maximum protective effect against ROS induced cell damage in the HDP cells occurs following pretreatment with 10 μM Troxerutin. Treatment with H₂O₂ alone decreases cell viability to 77.33±2.44%; however, pretreatment with 10 μM Troxerutin maintains cell viability at 90.88±2.24% following H₂O₂ exposure (P<0.05). At concentrations of 5 and 10 μM, pretreatment with Troxerutin causes a decrease in the number of cells in the sub G1 phase, indicative of cell death. In the control and Troxerutin-only-treated cells, 3.58±0.15 and 0.89±0.11% are 2′7′-dichlorofluorescein (DCF)-positive (P<0.05), whereas treatment with H₂O₂ alone increases the level of ROS to 46.36±2.33%. The cells pretreated with Troxerutin are 19.92±1.95% DCF-positive following H₂O₂ treatment, indicating that Troxerutin reduces the H₂O₂-induced production of ROS in the HDP cells .

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Troxerutin effectively lowers body weight and obesity-related metabolic parameters in high-fat diet (HFD)-treated mice. Oral administration of Troxerutin notably inhibits those liver injuries in HFD-treated mice, restores glucose intolerance and insulin signaling, and diminishes hepatic gluconeogenesis in HFD-treated mice. Troxerutin remarkably inhibits the nuclear translocation of NF-κB p65, as well as the expressions of its target genes, in the livers of HFD-treated mice. Troxerutin also depresses endoplasmic reticulum (ER) stress-mediated Nucleotide oligomerization domain (NOD) activation in HFD-treated mouse livers. Lipid depositions in tunica intimae and tunica media are attenuated in Troxerutin-treated diabetic rats compare with untreated diabetic rats. Structural disarrangement and deformity of smooth muscle cells in aortic tissue of Troxerutin-treated diabetic rats are considerably lower than histology of untreated diabetic aorta. Administration of Troxerutin for four weeks to diabetic rats significantly reduces the level of malondialdehyde (MDA) compare to that of untreated diabetic rats (P<0.01).

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

结构分类

来源

参考文献

[1]. Lim KM, et al. Analysis of changes in microRNA expression profiles in response to the troxerutin-mediated antioxidant effect in human dermal papilla cells. Mol Med Rep. 2015 Aug;12(2):2650-60. [Information]

[2]. Zhang Z, et al. Troxerutin Attenuates Enhancement of Hepatic Gluconeogenesis by Inhibiting NOD Activation-Mediated Inflammation in High-Fat Diet-Treated Mice. Int J Mol Sci. 2016 Dec 25;18(1). pii: E31. [Information]

[3]. Badalzadeh R, et al. Beneficial effect of troxerutin on diabetes-induced vascular damages in rat aorta: histopathological alterations and antioxidation mechanism. Int J Endocrinol Metab. 2015 Apr 30;13(2):e25969. [Information]

溶解度数据

体外研究:

DMSO : 100 mg/mL (134.65 mM; Need ultrasonic and warming)

H₂O : ≥ 50 mg/mL (67.32 mM)

* "≥" means soluble, but saturation unknown.

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.3465 mL	6.7324 mL	13.4647 mL
5 mM	0.2693 mL	1.3465 mL	2.6930 mL
10 mM	0.1346 mL	0.6732 mL	1.3465 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 24 mg/mL (32.32 mM); Clear solution; Need ultrasonic
2.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (3.37 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.37 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
3.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (3.37 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.37 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.37 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.37 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation